Bronstein, Gewirtz & Grossman, LLC Encourages AdaptHealth Corp. (AHCO) Shareholders to Inquire about Securities Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against AdaptHealth Corp. (AHCO) after the company reported significantly lower-than-expected Q2 revenue, a GAAP loss, and a substantial reduction in full-year guidance. Shareholders who purchased AdaptHealth securities are encouraged to contact the firm to assist with the investigation. The investigation stems from a 26% share drop following the disappointing financial results.
Bronstein, Gewirtz & Grossman, LLC Is Investigating AdaptHealth Corp. (AHCO) And Encourages Shareholders to Connect
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of AdaptHealth Corp. (NASDAQ: AHCO) after the company reported disappointing second-quarter results and significantly reduced its full-year guidance. AdaptHealth's shares fell by as much as 26% following the announcement of lower-than-expected revenue, a GAAP loss with a goodwill impairment charge, and a substantial cut to its 2026 outlook. The firm encourages affected AdaptHealth investors to contact them for more information or to assist with the investigation.
AdaptHealth Breach Exposed Health Records of One in 13 Vermonters
A data breach at AdaptHealth, a durable medical equipment provider, exposed the health records of 48,090 Vermonters, representing about one in 13 residents. This incident accounts for 57% of all Vermonters affected by data breaches reported to the state Attorney General's Office since April 2026. The breach, attributed to social engineering targeting a third-party contractor's account, allowed access to patient management systems and electronic health record portals.
AdaptHealth breach exposed health records of one in 13 Vermonters
A data breach at AdaptHealth, a durable medical equipment provider, exposed the health records of 48,090 Vermonters, affecting about one in every 13 residents. This incident accounts for 57% of all data breaches reported to the Vermont Attorney General's Office since April 2026. The breach, attributed to social engineering rather than a hack, involved a compromised third-party contractor's account, leading to the exfiltration of patient data by the criminal group ShinyHunters.
AdaptHealth Corp. (NASDAQ:AHCO) Given Average Recommendation of "Moderate Buy" by Brokerages
AdaptHealth Corp. (NASDAQ:AHCO) has received an average rating of "Moderate Buy" from analysts, despite a significant quarterly earnings miss where the company reported an adjusted loss of $0.99 per share against an expected $0.17 earnings. The stock is currently trading near its 52-week low. Insider activity shows a director recently increased their stake, while institutional investors hold a substantial portion of the company's shares.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against AdaptHealth Corp. (AHCO) and Encourages Shareholders to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has announced an investigation into AdaptHealth Corp. (AHCO) following a significant drop in its shares on August 5, 2026. The decline occurred after AdaptHealth reported second-quarter revenue well below expectations, a GAAP loss including a substantial goodwill impairment charge, and a significantly reduced full-year guidance. The law firm is encouraging shareholders to learn more about the investigation and potentially assist in claims.
AdaptHealth (NASDAQ:AHCO) Downgraded to "Sell" Rating by Wall Street Zen
Wall Street Zen has downgraded AdaptHealth (NASDAQ:AHCO) from a "hold" to a "sell" rating, despite the broader consensus of "Moderate Buy" among analysts with an average price target of $10.29. The company's shares opened at $5.81, near their 52-week low, and below their 50-day and 200-day moving averages. Insider transactions show a director purchasing shares, while institutional investors hold a significant portion of the stock.
AdaptHealth Corp. Data Breach: Edelson Lechtzin LLP Launches Investigation Into Exposure of Personal Information
Edelson Lechtzin LLP, a national class action law firm, is investigating a data breach at AdaptHealth Corp. that exposed patient data. The breach, disclosed on July 2, 2026, involved a social engineering attack that compromised a third-party contractor's credentials, leading to unauthorized access to patient management systems and stolen personal and health information. The firm is offering free case evaluations to individuals affected by the incident.
AdaptHealth Corp. Data Breach: Edelson Lechtzin LLP Launches Investigation Into Exposure of Personal Information
Edelson Lechtzin LLP is investigating a data breach at AdaptHealth Corp. (Nasdaq: AHCO) that exposed patient data, including personally identifiable information (PII) and protected health information (PHI). The incident, disclosed on July 2, 2026, involved unauthorized access to systems via a social engineering attack on a third-party contractor, with the threat group ShinyHunters claiming responsibility. The firm is offering free case evaluations to affected individuals who may face risks of identity theft and fraud.
AdaptHealth Corp. (AHCO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of AdaptHealth Corp. (NASDAQ: AHCO) purchasers following a significant drop in share price. The investigation stems from AdaptHealth's Q2 2026 earnings report, which showed revenue and adjusted EBITDA well below expectations, a GAAP loss due to a goodwill impairment, and a substantial reduction in full-year guidance. Shareholders are encouraged to contact the firm to learn more and assist with the investigation.
Kenneth Samet Bought 94% More Shares In AdaptHealth
Independent Director Kenneth Samet recently increased his holding in AdaptHealth Corp. by 94%, purchasing US$150k worth of shares at US$6.38 each. This significant insider purchase, the largest in the last year, signals optimism about the company despite it having made a loss during the last year. Insiders own 8.4% of AdaptHealth, valued at approximately US$58m, indicating alignment with shareholder interests.
Bronstein, Gewirtz & Grossman, LLC Is Investigating AdaptHealth Corp. (AHCO) And Encourages Investors to Connect
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against AdaptHealth Corp. (AHCO) after the company reported significantly lower-than-expected Q2 2026 revenue and adjusted EBITDA, along with a substantial reduction in full-year guidance. The firm encourages investors who purchased AdaptHealth securities to connect with them to assist in the investigation, highlighting that they operate on a contingency fee basis. This investigation stems from AdaptHealth's share price fall following its Q2 earnings report and revised outlook.
AdaptHealth Corp. (AHCO) Securities Investigation Notice - Levi & Korsinsky
Levi & Korsinsky, LLP has issued a securities investigation notice for AdaptHealth Corp. (AHCO) after the company reported second-quarter 2026 revenue and earnings significantly below analyst expectations. Shares of AdaptHealth fell as much as 26% following the announcement of a $0.99 GAAP loss per share and a revenue miss of over $100 million. The law firm is investigating potential securities law violations and encourages shareholders who suffered losses to submit their information.
AdaptHealth misses Q2 revenue and earnings estimates, shares drop 26%.
AdaptHealth Corp. (AHCO) reported a significant miss on Q2 2026 revenue and earnings estimates, with revenue at $740.3 million against an anticipated $847 million, and a GAAP loss of $0.99 per share compared to an expected loss of $0.15. This poor performance led to a 26% drop in shares. The company is now under investigation for potential misleading statements regarding its financial outlook, and affected investors may be eligible for legal action.
Kenneth Samet Bought 94% More Shares In AdaptHealth
Independent Director Kenneth Samet recently purchased US$150k worth of AdaptHealth (NASDAQ:AHCO) shares at US$6.38 each, increasing his holding by 94%. This insider buying activity, along with other purchases totaling US$511k over the last year, suggests a bullish sentiment despite the company's recent loss. Insiders own 8.4% of the company, indicating some alignment with shareholder interests.
AdaptHealth | 8-K: ADAPTHEALTH CORP. ANNOUNCES SECOND QUARTER 2026 RESULTS
This 8-K filing announces AdaptHealth Corp.'s second-quarter 2026 financial results. The document serves as a regulatory notification to shareholders and the public regarding the company's recent financial performance. Further details would typically be found within the full 8-K filing itself.
Time To Worry? Analysts Just Downgraded Their AdaptHealth Corp. (NASDAQ:AHCO) Outlook
Analysts have significantly downgraded their near-term forecasts for AdaptHealth Corp. (NASDAQ:AHCO), cutting both revenue and earnings per share estimates for 2026. The consensus now expects revenues of US$2.9 billion, a 14% reduction, and a loss per share of US$1.27, compared to previous profit forecasts. The price target has also fallen by 35% to US$9.14, reflecting concerns over the company's anticipated underperformance relative to the broader industry.
AdaptHealth at Canaccord Genuity’s 46th annual growth conference: refocus deepens
AdaptHealth discussed its business transition at Canaccord Genuity's 46th Annual Growth Conference, focusing on organic growth, debt reduction, and core home medical equipment lines after divesting its diabetes business. The company highlighted strong sleep care demand and 16% Q2 2024 revenue growth, despite facing challenges with a major West Coast contract and a supplier dispute. Management expressed confidence in resolving operational issues and leveraging technology to streamline patient services.
AdaptHealth (NASDAQ:AHCO) Trading Up 10.5% on Insider Buying Activity
AdaptHealth (NASDAQ:AHCO) saw its stock price increase by 10.5% due to significant insider buying activity, specifically by Director Kenneth A. Samet, who increased his holdings by 93.7% with a purchase worth nearly $150,000. Analyst sentiment is mixed but leans positive, with seven analysts rating the stock a "Buy" and an average target price of $10.29. Institutional ownership is substantial at 82.67%, indicating strong institutional confidence in the home medical equipment provider.
AdaptHealth Sells Diabetes Unit to Sharpen Focus on Sleep, Respiratory Growth
AdaptHealth (NASDAQ:AHCO) is selling its diabetes business to Cardinal Health and exiting certain e-commerce operations to streamline its focus on sleep, respiratory, and home medical equipment. Despite a 16% revenue growth in the second quarter, the company is addressing higher-than-expected service costs from a new West Coast capitated contract. Management is prioritizing organic growth in sleep care, reducing leverage, and pursuing targeted acquisitions in its core segments.
Adapthealth director Kenneth Samet buys $149,930 in shares
AdaptHealth Corp. director Kenneth Samet recently purchased 23,500 shares of company stock for $149,930, bringing his total holdings to 48,569 shares. This insider purchase occurs while AHCO stock is trading near its 52-week low, with InvestingPro analysis suggesting it is undervalued. The company recently reported a significant Q2 earnings miss due to higher costs, leading Truist Securities to lower its price target while maintaining a Buy rating.
Adapthealth director Dale Wolf buys $244,600 in company stock
Dale B. Wolf, a director at AdaptHealth Corp. (NASDAQ:AHCO), recently purchased 40,000 shares of company stock for $244,600 in early August 2026, with prices between $5.83 and $6.37 per share. These insider purchases occurred while AHCO shares traded near their 52-week low, and InvestingPro analysis suggests the stock is undervalued. This comes despite AdaptHealth reporting a disappointing second quarter with a significant loss per share and missed revenue targets, though revenue still grew year-over-year.
Time To Worry? Analysts Just Downgraded Their AdaptHealth Corp. (NASDAQ:AHCO) Outlook
Analysts have significantly downgraded their near-term forecasts for AdaptHealth Corp. (NASDAQ:AHCO), cutting revenue and EPS estimates due to a more pessimistic outlook. The consensus now projects a 14% reduction in revenue to US$2.9 billion in 2026 and an anticipated loss per share of US$1.27, compared to previous expectations of profit. This revision suggests that AdaptHealth's revenue growth will lag behind the wider healthcare services industry.
AdaptHealth (NASDAQ:AHCO) Director Purchases $149,930.00 in Stock
AdaptHealth (NASDAQ:AHCO) Director Kenneth Samet recently purchased 23,500 shares for $149,930, increasing his stake by 93.74%. Despite the purchase and analysts' "Moderate Buy" rating with a $10.29 price target, the stock fell 8.3% to $5.22, nearing its one-year low, with trading volume more than doubling its average. Institutional investors hold 82.67% of the company, which provides home medical equipment and services.
Time To Worry? Analysts Just Downgraded Their AdaptHealth Corp. (NASDAQ:AHCO) Outlook
Analysts have significantly downgraded their near-term forecasts for AdaptHealth Corp. (NASDAQ:AHCO), cutting both revenue and earnings per share estimates for 2026. The consensus now projects a substantial revenue reduction and a loss per share, leading to a 35% drop in the consensus price target. These revised expectations suggest AdaptHealth's sales will decline significantly, underperforming the broader industry.
Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving AdaptHealth Corp. (AHCO)
Levi & Korsinsky, LLP is investigating AdaptHealth Corp. (AHCO) due to a significant stock drop after the company reported a GAAP loss of $0.99 per share in Q2 2026, contrary to expected profits, and simultaneously reduced its full-year 2026 revenue and adjusted EBITDA outlook. Investors who purchased AHCO shares and suffered losses are encouraged to contact the firm for a free case evaluation regarding potential securities law violations. The investigation focuses on whether AdaptHealth made materially false or misleading statements regarding its financial outlook.
Time To Worry? Analysts Just Downgraded Their AdaptHealth Corp. (NASDAQ:AHCO) Outlook
Analysts have significantly downgraded their outlook for AdaptHealth Corp. (NASDAQ:AHCO), cutting both revenue and earnings per share estimates for 2026. The consensus now anticipates a 14% reduction in sales and a projected loss per share, contrasting sharply with previous forecasts of profitability. This bearish revision has also led to a 35% drop in the consensus price target, signaling concerns about the company's future performance relative to the broader industry.
ADAPTHEALTH CORP. : LEERINK PARTNERS CUTS TARGET PRICE TO $7 FROM $12
Leerink Partners has reduced its target price for AdaptHealth Corp. (AHCO) shares from $12 to $7. This change reflects an updated outlook from the investment firm regarding the company's valuation. The article, sourced from Reuters, provides this key financial adjustment.
AdaptHealth Corp. $AHCO Shares Sold by Reinhart Partners LLC.
Reinhart Partners LLC reduced its stake in AdaptHealth Corp. by 26.4% in the second quarter, selling over 2.6 million shares but still retaining a significant holding. Despite this sale, other institutional investors increased their positions in AHCO. The stock currently holds a "Moderate Buy" consensus rating from analysts, with a target price of $10.29, though it has recently traded near its one-year low.
AdaptHealth Corp. Just Missed Earnings; Here's What Analysts Are Forecasting Now
AdaptHealth Corp. (NASDAQ:AHCO) shares plunged 43% following its second-quarter results, where revenues fell short of estimates and the company reported a statutory loss instead of a forecasted profit. Analysts have significantly cut revenue forecasts for 2026, now anticipating a decline and a loss per share. The average price target for AdaptHealth has also dropped by 30%, reflecting a negative shift in sentiment and valuation expectations.
AHCO Investors Have Opportunity to Join AdaptHealth Corp. Fraud Investigation with SBS Law
Schall, Brown & Schwartz LLP (SBS) is investigating potential securities law violations by AdaptHealth Corp. (NASDAQ: AHCO) on behalf of its investors. This investigation follows AdaptHealth's Q2 2026 financial results, where the company missed earnings estimates and significantly cut its full-year guidance, leading to a 38% drop in stock price. Investors who suffered losses are encouraged to contact SBS to discuss their rights.
AHCO Investors Have Opportunity to Join AdaptHealth Corp. Fraud Investigation with SBS Law
Schall, Brown & Schwartz LLP (SBS) has launched an investigation into AdaptHealth Corp. (AHCO) for potential securities law violations. This follows AdaptHealth's Q2 2026 financial results, which missed earnings estimates and led to a significant cut in full-year guidance, causing the stock to drop over 38%. SBS is encouraging affected shareholders to join the fraud investigation.
AdaptHealth Corp. Just Missed Earnings; Here's What Analysts Are Forecasting Now
AdaptHealth Corp. (NASDAQ:AHCO) experienced a significant share price drop and missed its second-quarter earnings, reporting lower revenues and a statutory loss instead of the forecasted profit. Following these results, analysts have drastically cut their revenue estimates for 2026 and now predict a loss, leading to a 30% reduction in the average price target. The company's revenue growth is now expected to significantly underperform the wider industry.
AHCO Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into AdaptHealth Corp. (AHCO)
Levi & Korsinsky is investigating potential securities law violations concerning AdaptHealth Corp. (AHCO) after its shares dropped by as much as 26%. This decline followed the company's Q2 revenue of $740.3 million, which missed expectations, a $0.99 GAAP loss, a $144.2 million goodwill impairment, and a significant reduction in its full-year guidance. Shareholders who suffered losses are encouraged to contact Levi & Korsinsky for a free evaluation.
AdaptHealth Corp. Just Missed Earnings; Here's What Analysts Are Forecasting Now
AdaptHealth Corp. (NASDAQ:AHCO) shares plunged 43% after missing Q2 earnings estimates, with revenues falling 13% short and the company reporting a statutory loss instead of a forecasted profit. Analysts have significantly cut revenue forecasts and now anticipate a loss for 2026, leading to a 30% reduction in the average price target. The company's revenue is expected to decline substantially, underperforming the wider industry.
AHCO SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving AdaptHealth Corp.
SueWallSt, powered by Levi & Korsinsky LLP, has initiated an investigation into AdaptHealth Corp. (NASDAQ: AHCO) after the company significantly lowered its full-year 2026 revenue and adjusted EBITDA guidance, causing a stock drop of up to 26%. The investigation focuses on whether AdaptHealth made misleading statements regarding its financial outlook. Investors who suffered losses after purchasing AHCO shares are encouraged to contact SueWallSt for a free case evaluation.
AHCO SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving AdaptHealth Corp.
SueWallSt, powered by Levi & Korsinsky LLP, has launched an investigation into AdaptHealth Corp. (AHCO) after the company drastically lowered its full-year 2026 revenue guidance, causing a significant stock price drop. The investigation focuses on whether AdaptHealth made misleading statements regarding its financial outlook, particularly after CFO Jason Clemens raised initial guidance but later reset it due to undisclosed factors. Investors who suffered losses after purchasing AHCO shares are encouraged to contact SueWallSt for a free case evaluation.
Securities Fraud Investigation Into AdaptHealth Corp. (AHCO) Announced – Shareholders Who Lost Money Urged to Contact The Law Offices of Frank R. Cruz
The Law Offices of Frank R. Cruz has announced a securities fraud investigation into AdaptHealth Corp. (AHCO) following a significant drop in its stock price. This investigation comes after AdaptHealth reported a substantial earnings miss and cut its full-year 2026 adjusted EBITDA guidance, citing issues with its West Coast Capitated Contract and unexpected price increases. Shareholders who lost money are urged to contact the law firm to learn about potentially pursuing a claim.
AdaptHealth Corp. Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into AdaptHealth Corp. (AHCO)
Levi & Korsinsky is investigating AdaptHealth Corp. (AHCO) after the company significantly cut its full-year 2026 adjusted EBITDA guidance. The reduction from an initial range of $680 million-$730 million to approximately $490 million-$520 million, a drop of $190 million-$210 million, caused a stock decline of up to 26%. The investigation focuses on whether the company made misleading statements regarding its financial outlook and the normalization of labor costs prior to this guidance revision.
Stocks making big moves yesterday: AdaptHealth, UL Solutions, Ball, Tidewater, and Wayfair
This article highlights several stocks that experienced significant movement yesterday, August 4, 2026, due to their second-quarter earnings reports. AdaptHealth and UL Solutions saw declines after reporting disappointing results, while Ball's strong earnings were overshadowed by profitability concerns. In contrast, Tidewater and Wayfair both saw their stock prices rise following positive investor reactions to their respective quarterly performances.
AdaptHealth Corp. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:AHCO)
AdaptHealth Corp. published its Q2 2026 earnings call presentation on August 5, 2026. The company reported an EPS of -$0.07, missing estimates by $0.23, and revenue of $740.31M, down 7.50% year-over-year and missing estimates by $106.47M. This information was shared in conjunction with their earnings call.
AdaptHealth Agrees to Sell Diabetes Business for $235M, Subject to Adjustments
AdaptHealth Corp. announced its second-quarter 2026 financial results, revealing a definitive agreement to sell its Diabetes Health business for $235 million in cash. This divestiture is part of AdaptHealth's strategy to focus on its core Sleep Health, Respiratory Health, and Wellness-at-Home segments. The company also revised its full-year 2026 financial guidance, lowering its Adjusted EBITDA forecast to $490 million to $520 million due to the sale, impacts from a capitated agreement, and manufacturer price increases.
AdaptHealth Corp. 2Q 2026: Revenue $740.31M, Net income ($133.93M), EPS ($0.99) — 10-Q Summary
AdaptHealth Corp. reported its second-quarter 2026 results, showing a 12.7% increase in revenue year-over-year to $740.31 million. Despite revenue growth, the company recorded a net loss of $133.93 million and a diluted EPS of ($0.99), a significant decrease compared to the prior year's profit. The company highlighted revenue growth from organic sources and new capitated contracts, alongside challenges from inflation and a cybersecurity incident.
AHCO INVESTOR ALERT: Investigation of AdaptHealth Corp. Announced by Holzer & Holzer, LLC
Holzer & Holzer, LLC has announced an investigation into AdaptHealth Corp. (NASDAQ: AHCO) regarding potential violations of federal securities laws. This comes after AdaptHealth revised its financial guidance and reported a decrease in cash flow from operations and negative free cash flow for Q2 2026, leading to a drop in its stock price. The law firm is encouraging investors who suffered losses to contact them to discuss their legal rights.
Investigation launched into AdaptHealth after revised guidance and Q2 cash flow drop. AHCO $6.71 -$4.12 -38.04%
Holzer & Holzer, LLC has launched an investigation into AdaptHealth Corp. following the company's revised financial guidance and second-quarter 2026 results. AdaptHealth reported a decrease in cash flow from operations and a negative free cash flow, attributing the decline to the full-scale launch and transition of its West Coast capitated partnership. The stock price dropped significantly after the announcement, leading to offers for legal action from affected investors.
Why AdaptHealth (AHCO) Stock Is Trading Lower Today
AdaptHealth Corp. (AHCO) stock significantly dropped by 39.5% after reporting disappointing second-quarter results and drastically cutting its full-year financial guidance. The company posted a loss of $0.99 per share and revenue of $740.3 million, both falling short of analyst expectations, and attributed the lowered outlook to West Coast partnership issues and unexpected price increases. This follows a previous significant drop related to profitability challenges in late 2025.
AdaptHealth lowers outlook as new contract, manufacturer costs pressure margins
AdaptHealth has reduced its full-year financial outlook due to pressures from a new capitated agreement and unexpected manufacturer price increases. Despite a 12.7% increase in second-quarter revenue, implementation costs for a major contract and a $30 million impact from a manufacturer price hike negatively affected margins. The company is actively addressing these cost pressures and has announced a workforce restructuring to generate annualized savings.
Why AdaptHealth (AHCO) Stock Is Trading Lower Today
AdaptHealth (AHCO) stock significantly dropped after the company reported disappointing Q2 results and drastically cut its full-year 2026 financial guidance. The healthcare services provider posted a substantial loss per share and missed revenue expectations, attributing the revised outlook to partnership challenges and unexpected price increases. This follows a previous significant drop related to profitability challenges in Q4 2025.
AdaptHealth Shares Sink After Earnings Miss and Lower Full-Year Guidance
AdaptHealth (NASDAQ:AHCO) shares plummeted after the company reported second-quarter 2026 results that missed Wall Street expectations and significantly cut its full-year financial outlook. The home medical equipment provider posted a quarterly loss of $0.99 per share and revenue of $740.3 million, both falling short of analyst estimates. The reduced guidance reflects impacts from the sale of its Diabetes Health business, a capitated contract, manufacturer price increases, and a goodwill impairment charge.
Adapthealth Corp stock hits 52-week low at 6.68 USD
Adapthealth Corp (AHCO) stock has reached a 52-week low of $6.68, despite InvestingPro analysis suggesting it may be undervalued and analysts predicting profitability this year with an EPS forecast of $0.94. This low follows disappointing Q2 results where the company missed analyst expectations for both earnings and revenue, though it did experience 12.7% year-over-year revenue growth. Investors are closely watching the stock for potential turnaround signs.
